Phase 4
N=54
Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients
Opiate Addiction
Bottom Line
View on ClinicalTrials.gov: NCT00879996 ↗Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Jul 2012
Primary outcome: Primary: Number of Participants Retained in Treatment — 13; 13 participants — p=0.77
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Methadone (Drug); Buprenorphine/naloxone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- State University of New York at Buffalo
- Primary completion
- Oct 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Retained in Treatment |
13; 13 | 0.77 |
| SECONDARY Numerical Rating Score for Pain |
5.4; 5.6 | <0.043 sig |
| SECONDARY Numerical Rating Score for Functioning |
5.0; 5.3 | <0.665 |
| SECONDARY Self-reported Illicit Opioid Use |
0; 5 | <0.039 sig |
Summary
The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.
Eligibility Criteria
Inclusion Criteria
- chronic back pain
- opioid addiction
- not successful with abstinence
- at least 18 years old
- able to understand spoken English
- live in Western New York State (Erie or Niagara county)
- have health insurance or ability to pay for health care
- no methadone or buprenorphine treatment within past year
- not member of a vulnerable population (e.g., pregnancy, prisoner)
Exclusion Criteria
- homelessness
- unable to give consent (e.g., dementia, psychosis)
- serious heart or lung disease
- taking a medication that could interact with methadone or buprenorphine
- pregnancy
Data sourced from ClinicalTrials.gov (NCT00879996). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.